Core Viewpoint - Weikang Pharmaceutical reported a decline in revenue and net profit for 2024, with a focus on enhancing operational management and expanding its marketing network in 2025 [1][4] Financial Performance - In 2024, Weikang achieved revenue of 351 million yuan and a net profit of -147 million yuan; in Q1 2025, revenue was 69.78 million yuan with a net profit of -9.85 million yuan [1] - The company recorded non-recurring gains of 88.25 million yuan from the sale of its subsidiaries, while also accounting for fixed asset impairment losses of 76.20 million yuan [1] R&D and Innovation - Weikang emphasizes R&D and has established multiple research platforms, collaborating with industry experts and academic institutions [2] - The company is focusing on innovative drug development, with ongoing projects including two Class 1 traditional Chinese medicine (TCM) innovations and several Class 2 and Class 3 TCM new drugs [2] Product Highlights - The core product, Yinhuang Diban, has shown significant clinical effectiveness in treating various throat infections and has completed successful clinical trials for new indications [3] - Yinhuang Diban has received multiple accolades, including being ranked first in the retail terminal adult cold medication category in 2024 [3] Future Strategy - In 2025, Weikang plans to enhance its core business direction, improve operational management, and strengthen its marketing network to achieve performance targets [4] - The company aims to continue its focus on the health industry and cultivate new growth points aligned with its development strategy [4]

4月28日晚，维康药业（300878）(300878.SZ)发布2024年年度报告及2025年第一季度报告。财报显示， 2024年公司实现营业收入3.51亿元，归母净利润-1.47亿元；2025年一季度实现营业收入6977.59万元， 归母净利润-985.47万元。 对于此次业绩，维康药业表示主要归于以下几点原因，一是公司于2024年9月完成了从事医药零售业务 的全资孙公司浙江维康和浙江维康大药房的股权转让，取得投资收益8824.92万元，形成非经常性损 益，同时计提固定资产减值准备7620.28万元；二是公司产品销售收入和毛利率均有所下滑；三是公司 产品销售退回影响了2024年度特别是2024年四季度的收入和利润数据；四是公司医药大健康产业园一 期、二期固定资产折旧增加较多影响公司利润。 尽管面临上述挑战，维康药业仍通过研发创新及核心单品突破，持续强化技术壁垒。叠加中药行业政策 红利释放及成本端压力缓解，公司业绩有望逐季修复，步入高质量发展新阶段。 注重研发创新，技术壁垒持续强化 维康药业长期聚焦于新药研发和重点产品的二次开发，邀请了包括多名院士在内的行业权威教授、研究 员担任技术与研发顾问，并与高校、院士 ...